Synaptogenix, Inc. (SNPX)
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
$4.28M
Dr. Alan J. Tuchman M.D., MBA(FAAN)
4.00
New York, NY
Dec 31, 2020
0.32
$10.27
11.87
12.05
0.00%
-0.46
0.07
0.00
11.87
-12.63%
-13.72%
Similar stocks (5)
Annovis Bio, Inc.
ANVS
INmune Bio, Inc.
INMB
Reviva Pharmaceuticals Holdings, Inc.
RVPH
Cyclo Therapeutics, Inc.
CYTH
Alzamend Neuro, Inc.
ALZN
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (5)
Annovis Bio, Inc.
ANVS
INmune Bio, Inc.
INMB
Reviva Pharmaceuticals Holdings, Inc.
RVPH
Cyclo Therapeutics, Inc.
CYTH
Alzamend Neuro, Inc.
ALZN
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%